Genetic Modifiers of Progression-Free Survival in Never-Smoking Lung Adenocarcinoma Patients Treated with First-Line Tyrosine Kinase Inhibitors

Rationale: Patients with non–small cell lung cancer (NSCLC) with mutated epidermal growth factor receptor (EGFR) are relatively sensitive to EGFR–tyrosine kinase inhibitor (TKI) treatment and have longer progression-free survival (PFS) when treated with EGFR-TKI compared with platinum-based chemothe...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Am J Respir Crit Care Med
Autori principali: Chang, I-Shou, Jiang, Shih Sheng, Yang, James Chih-Hsin, Su, Wu-Chou, Chien, Li-Hsin, Hsiao, Chin-Fu, Lee, Jih-Hsiang, Chen, Chih-Yi, Chen, Chung-Hsing, Chang, Gee-Chen, Wang, Zhaoming, Lo, Fang-Yi, Chen, Kuan-Yu, Wang, Wen-Chang, Chen, Yuh-Min, Huang, Ming-Shyan, Tsai, Ying-Huang, Su, Yu-Chun, Hsieh, Wan-Shan, Shih, Wen-Chi, Shieh, Shwn-Huey, Yang, Tsung-Ying, Lan, Qing, Rothman, Nathaniel, Chen, Chien-Jen, Chanock, Stephen J., Yang, Pan-Chyr, Hsiung, Chao A.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Thoracic Society 2017
Soggetti:
Original Articles
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5363976/
https://ncbi.nlm.nih.gov/pubmed/27669169
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1164/rccm.201602-0300OC
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi